Novozymes and Upperton Collaborate on Nanoparticle Drug Technology
Novozymes (Bagsvaerd, Denmark) will collaborate with Upperton Limited (Nottingham, UK), a company specializing in novel nanoparticle-based drug delivery systems.
Novozymes (Bagsvaerd, Denmark) will collaborate with Upperton Limited (Nottingham, UK), a company specializing in novel nanoparticle-based drug delivery systems. The agreement will focus on the commercial exploitation of the jointly-owned rP-nano technology, a highly targeted drug delivery system that use the natural binding properties of recombinant protein nanoparticles to enhance drug and gene bioavailability.
Under the terms of the agreement Upperton will use rP-nano technology to generate nanoparticles from recombinant proteins expressed in Novozymes’ proprietary, yeast-based expression system. The, rP-nano technology can generate precisely sized nanoparticles within the range of 10 nm to 120 nm and can be optimized for enhanced permeability and retention effect. The nanoparticles produced through this process retain the natural binding properties of the recombinant proteins from which they are made, and bind to specific cell types to enable more targeted drug delivery and improved bioavailability.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
